Securities code: 688068 securities abbreviation: Beijing Hotgen Biotech Co.Ltd(688068) Announcement No.: 2022-004 Beijing Hotgen Biotech Co.Ltd(688068)
Announcement of serious abnormal fluctuations in stock trading
The board of directors and all directors of the company guarantee that there are no false records, misleading statements or major omissions in the contents of this announcement, and bear legal liabilities for the authenticity, accuracy and integrity of its contents according to law.
Important content tips:
The deviation of daily closing price of Beijing Hotgen Biotech Co.Ltd(688068) (hereinafter referred to as “the company”) shares has reached 100% in 10 consecutive trading days from December 31, 2021 to January 14, 2022. According to the trading rules of Shanghai Stock Exchange and the special provisions on stock trading on the science and Innovation Board of Shanghai Stock Exchange The relevant provisions of the detailed rules for real-time monitoring of abnormal trading of stocks on the science and Innovation Board of Shanghai Stock Exchange (for Trial Implementation) belong to serious abnormal fluctuations.
After the company’s self-examination and written verification to the controlling shareholder and actual controller, as of the disclosure date of this announcement, it is confirmed that there are no major events or important information that should be disclosed but not disclosed.
Profit adjustment risk accumulated by the continuous rise of the company’s stock price: the deviation of the daily closing price of the company’s stock in 10 consecutive trading days from December 31, 2021 to January 14, 2022 has reached 100%, and the continuous rise of the stock price has accumulated more profit adjustment risk. The company specially reminds investors to pay attention to investment risks, avoid following the trend of speculation, make rational decisions and invest prudently.
Europe and other COVID-19 products testing market competition risk: New Coronavirus antigen self testing reagent products obtained the EU CE certification and British MHRA, France ANSM self testing registration / filing, has not yet obtained the US market access certification, and there are many similar or other testing products in the European market, the company’s products will face fierce market competition risk.
Uncertain risk of performance growth: affected by many factors such as overseas epidemic development and epidemic prevention and control policies, market competition, path selection of international epidemic on technical products, product competitiveness and channel ability of the company, customer recognition and so on, the sales and profit contribution of the above covid-19 products are relatively uncertain.
Other risks leading to the uncertainty of the company’s operating performance: there is some uncertainty whether the company’s future sales performance can continue to maintain a significant growth trend. It depends on the progress of global covid-19 epidemic prevention and control, the path selection of international epidemic for technical products, as well as the market competitiveness and channel capacity of the company’s products. Please pay attention to the investment risks.
1、 Details of abnormal fluctuations in stock trading
Within 10 consecutive trading days (from December 31, 2021 to January 14, 2022), the deviation of closing price increase has reached 100%. According to the trading rules of Shanghai Stock Exchange, special provisions on stock trading on the science and Innovation Board of Shanghai Stock Exchange, detailed rules for real-time monitoring of abnormal stock trading on the science and Innovation Board of Shanghai Stock Exchange (for Trial Implementation), it belongs to the situation of serious abnormal fluctuation in stock trading. 2、 Relevant information concerned and verified by the company
According to relevant regulations of Shanghai Stock Exchange, the company has conducted necessary verification on relevant issues. It is explained as follows:
(I) production and operation
According to the company’s self inspection, the company’s current production and operation activities are normal, the market environment and industrial policies have not been significantly adjusted, the production cost and sales have not fluctuated significantly, and the internal production and operation order is normal. (II) major events
After the company’s self-examination and sent a letter to Mr. Lin Changqing, the controlling shareholder and actual controller of the company, it was confirmed that as of January 14, 2022, there was no major information that should be disclosed but not disclosed, including but not limited to the planned M & A, share issuance, debt restructuring, business reorganization, asset divestiture and asset injection. (III) media reports, market rumors and hot concepts
The company has not found any media reports or market rumors that may have a great impact on the company’s stock trading price, and has not found any other major events that may have a great impact on the company’s stock price.
Except for the information disclosed by the company, there is no other major information that should be disclosed but not disclosed, and the information disclosed by the company in the early stage does not need to be corrected or supplemented.
(IV) other stock price sensitive information
Through the company’s self inspection and verification, the company’s directors, supervisors, senior managers, controlling shareholders and actual controllers did not buy or sell the company’s shares during the abnormal fluctuation of this stock transaction.
3、 Board statement
The board of directors of the company confirms that, except for the matters that have been disclosed in accordance with relevant provisions, the company has no matters that should be disclosed but not disclosed in accordance with relevant provisions such as the Listing Rules of science and Innovation Board of Shanghai Stock Exchange, or planning and intention related to such matters, The board of directors has not been informed of the information that should be disclosed but not disclosed in accordance with the Listing Rules of science and Innovation Board of Shanghai Stock Exchange and other relevant provisions, which may have a great impact on the trading price of the company’s shares and their derivatives.
4、 Relevant risk tips
(I) risk of unaudited financial data of performance advance announcement: the financial data of 2021 annual performance advance announcement has not been audited. Please pay attention to the investment risk.
(II) profit adjustment risk accumulated by the continuous rise of the company’s stock price: the daily closing price deviation of the company’s stock trading has reached 100% in 10 consecutive trading days from December 31, 2021 to January 14, 2022. The continuous rise of the stock price has accumulated a lot of profit adjustment risk. The company specially reminds investors to pay attention to investment risks, avoid following the trend of speculation, make rational decisions and invest prudently.
(III) the competition risks of COVID-19 products in Europe and other markets are fierce: the New Coronavirus antigen self testing reagent products of the company have obtained the EU CE certification and the self testing registration / filing of the British MHRA and France ANSM, have not yet obtained the US market access certification, and have been in many similar or other testing products in the European market. The products will face fierce market competition risks.
(IV) uncertain risk of performance growth: affected by many factors such as overseas epidemic development and epidemic prevention and control policies, market competition, path selection of international epidemic on technical products, product competitiveness and channel ability of the company, customer recognition and so on, the sales and profit contribution of the above covid-19 products are relatively uncertain. (V) other risks leading to the uncertainty of the company’s business performance: whether the company’s future sales performance can continue to maintain a significant growth trend, there is a certain uncertainty, which depends on the progress of global covid-19 epidemic prevention and control, the path selection of international epidemic for technical products, as well as the market competitiveness and channel ability of the company’s products, Please pay attention to investment risks.
The company solemnly reminds investors that China Securities News, Shanghai Securities News, securities daily and securities times are the designated information disclosure newspapers of the company and the website of Shanghai Stock Exchange（ http://www.sse.com.cn. ）Specify an information disclosure website for the company. All information of the company shall be subject to the information published in the above designated media. Please invest rationally and pay attention to investment risks.
5、 Online announcement attachment
(I) reply to the inquiry letter on Beijing Hotgen Biotech Co.Ltd(688068) abnormal fluctuations in stock trading.
It is hereby announced.
Beijing Hotgen Biotech Co.Ltd(688068) board of directors January 15, 2022
